Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploring new territory: considering the future.

M Schneider1

  • 1Clinic for Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany. schneider@rheumanet.org

Lupus
|April 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of bone size, not density, on the stiffness of the proximal part of normal and osteoporotic human femora.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1992
Same author

[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].

Zeitschrift fur Kardiologie·1992
Same author

Prescribing NSAIDs.

Orthopaedic review·1992
Same author

Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC].

International journal of immunopharmacology·1992
Same author

Laryngospasm during transtracheal high frequency jet ventilation.

Anaesthesia·1992
Same author

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.

British journal of cancer·1992

New therapies for lupus nephritis are needed to reduce toxicity and steroid use. Investigational treatments target B cells, cytokines, and specific antibodies, aiming for remission and improved patient outcomes.

Area of Science:

  • Rheumatology
  • Nephrology
  • Immunology

Background:

  • Current European League Against Rheumatism (EULAR) guidelines indicate mycophenolate mofetil is effective for lupus nephritis but lacks long-term data compared to cyclophosphamide.
  • There is a critical need for novel therapies to minimize treatment toxicity, reduce steroid dependence, and potentially achieve a cure for lupus nephritis.

Purpose of the Study:

  • To review emerging and investigational therapies for lupus nephritis.
  • To explore novel therapeutic targets and strategies beyond conventional immunosuppression.

Main Methods:

  • Literature review of current and investigational treatments for lupus nephritis.
  • Analysis of EULAR guidelines and therapeutic advancements.
  • Discussion of targeted therapies including B-cell, cytokine, and antibody-based approaches.

Related Experiment Videos

Main Results:

  • Rituximab shows promise in refractory cases, suggesting B-cell targeting is a viable strategy.
  • Other anti-cell therapies (epratuzumab, belimumab, alemtuzumab) and anti-cytokine treatments (infliximab, tocilizumab) are under investigation.
  • Novel targets include anti-double-stranded DNA antibodies, monocyte chemoattractant protein-1, and protein kinase CK2.

Conclusions:

  • A shift in therapeutic goals from survival to remission induction may improve outcomes in lupus nephritis.
  • Non-immunosuppressive strategies, including cardiovascular risk reduction, are important adjuncts.
  • Urinary mRNA measurement offers a sensitive, non-invasive method for monitoring therapeutic response, surpassing the predictive value of immunological tests.